Skip to main content

Table 3 Comparison of the predictive accuracy of the prognostic models

From: Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma

Models

Overall survival

Recurrence-free survival

C-index (95%CI)

Coefficient (95%CI)

P-value

C-index (95%CI)

Coefficient (95%CI)

P-value

CCL17

0.615 (0.563–0.667)

  

0.612 (0.555–0.670)

  

TNM

0.706 (0.652–0.760)

  

0.658 (0.601–0.719)

  

TNM + CCL17

0.751 (0.699–0.803)

0.045 (0.016–0.074)

0.003†

0.717 (0.657–0.776)

0.018 (0.022–0.093)

0.002†

SSIGN

0.632 (0.580–0.685)

  

0.674 (0.617–0.731)

  

SSIGN + CCL17

0.679 (0.620–0.738)

0.017 (0.014–0.079)

0.006†

0.720 (0.661–0.778)

0.045 (0.019–0.071)

0.001†

UISS

0.735 (0.688–0.781)

  

0.710 (0.658–0.762)

  

UISS + CCL17

0.771 (0.724–0.818)

0.036 (0.017–0.055)

<0.001†

0.752 (0.697–0.802)

0.047 (0.018–0.065)

0.001†

Nomogram

0.799 (0.754–0.844)

  

0.787 (0.735–0.840)

  

Nomogram vs SSIGN

 

0.167 (0.118–0.215)

<0.001‡

 

0.109 (0.064–0.155)

<0.001‡

Nomogram vs UISS

 

0.064 (0.030–0.099)

<0.001‡

 

0.073 (0.031–0.115)

=0.001‡

  1. C-index and 95%CI were calculated from 1000 bootstrap samples to protect from overfitting
  2. C-index concordance index, CI confidence interval, SSIGN Mayo clinic stage, size, grade, and necrosis score, UISS UCLA Integrated Staging System
  3. †Compared the c-index with the original model without CCL17 expression data; ‡ Compared the c-index of nomogram with SSIGN/UISS stratification in different patient groups